Trade with Eva: Analytics in action >>

Monday, July 27, 2020

-=MediciNova (MNOV) : SARS-CoV-2 vaccine joint development with BioComo and Mie University Japan

Co announced an agreement with BioComo and Mie University (Mie prefecture, Japan) for joint development of a SARS-CoV-2 vaccine using BC-PIV, a human parainfluenza virus type 2 vector developed by BioComo and Tetsuya Nosaka, M.D., Ph.D., professor of the Department of Microbiology and Molecular Genetics, Mie University Graduate School of Medicine. MediciNova has been granted exclusive worldwide development rights to use BC-PIV for SARS-CoV-2 vaccine development from BioComo and Mie University.

No comments:

Post a Comment